Tackling Prurigo Nodularis (PN): New Treatment Recommendations for Managed Care and Payer Professionals

Release Date: February 15, 2024
Expiration Date: August 31, 2025
Estimated Time to Complete Activity: 1.25 hours
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:


	Sarina B. Elmariah, MD, PhD, MPH Associate Professor, Dermatology Director, UCSF Center for Itch and Neurosensory Disorders University of California, San Francisco Click here for biography

	Steven S. Kheloussi, PharmD, MBA, FAMCP Manager, Clinical Pharmacy Highmark, Inc Click here for biography

	Drake Reiter, PharmD Director, Clinical and Payer Solutions Strategy RxAnte Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Given the recent FDA approval and expanding pipeline of novel agents, PN treatment recommendations will likely evolve as clinical trial results accumulate and are subsequently translated into clinical practice. Payers may restrict treatment coverage based on clinical trial inclusion/exclusion criteria, requiring patients with PN to have a certain number of lesions and an inadequate treatment response, intolerance, or contraindication to a high potency topical steroid. Based on current practice gaps and barriers, managed care and payer professionals lack knowledge and skills that can help lessen the burden of PN by facilitating patient education, multidisciplinary care, and timely access to appropriate treatments.

Educational Objectives
After completing this activity, the participant should be better able to:

Identify the clinical, economic, and social burden of PN
Review approved and emerging therapies for the treatment of PN including drug targets, route of administration, the latest clinical trial data, and appropriate access to therapy
Employ payer strategies to improve quality and care for patients with PN

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
PACE designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.25 contact hour (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-24-024-H01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hour.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Faculty*	*Reported Financial Relationship*
Sarina B. Elmariah, MD, PhD, MPH	Consultant/Advisor/Speaker: Bellus Health, Galderma, Incyte, Lilly, Pfizer, Sanofi-Regeneron Co-founder: New Frontier Bio
Steven S. Kheloussi, PharmD, MBA	Nothing to disclose.
Drake Reiter, PharmD	Nothing to disclose.

The PACE planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.